Related Experiment Video
Updated: Jul 29, 2025

Vessel-sparing Excision and Primary Anastomosis
Published on: January 7, 2019
Case report: Short-term eculizumab use in atypical HUS associated with Lemierre's syndrome and post-infectious
Sanober Sadiq1, Anatoly Urisman2, Onur Cil1
1Division of Nephrology, Department of Pediatrics, University of California, San Francisco, San Francisco, CA, United States.
Abstract:
Atypical hemolytic uremic syndrome (aHUS) is a rare disease caused by genetic abnormalities, infections, autoimmune diseases, drugs, and malignancies. Anti-C5 monoclonal antibody eculizumab is the mainstay of treatment of aHUS caused by the genetic defects of the alternative complement pathway. However, the utility of eculizumab in non-genetic forms of aHUS and the timing of treatment discontinuation remain controversial. Here, we report successful short-term eculizumab use in two young adult patients with aHUS due to rare infectious and autoimmune etiologies: Lemierre's syndrome and post-infectious glomerulonephritis, respectively. Eculizumab was rapidly discontinued in both patients with no aHUS recurrence during long-term follow-up. Considering its favorable safety profile with appropriate meningococcal prophylaxis, eculizumab can be considered as a treatment option for non-genetic aHUS.
More Related Videos
11:32Real-Time, High-Throughput Microscopic Quantification of Human Neutrophil Extracellular Trap Release and Assessing the Pharmacology of Antagonists
Published on: October 18, 2024
09:16Supervised Machine Learning for Semi-Quantification of Extracellular DNA in Glomerulonephritis
Published on: June 18, 2020
Related Concept Videos
Antiepileptic Drugs: Potassium Channel Activators
Ezogabine has gained approval as an adjunctive treatment...
Acute Kidney Injury IV: Diagnostic Studies and Prevention
Acute Pyelonephritis II: Diagnostic Studies and Management
Venous Thrombosis III: Interprofessional Care
Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care